ライフサイエンスコーパス: ACS

1 ACS events in TAVR recipients exhibited specific charact

2 ACS TQIP database study including patients with blunt se

3 ACS, ASA, AWS, and SBAS presidents' CVs, at the time of

4 ACS-ERRA is an online formative assessment that uses a k

5 comprising 66 patients each, namely group 1 (ACS patients without CP), group 2 (ACS patients with CP)

6 sing a quantitative protein microarray in 12 ACS patients and 16 healthy controls, and identified 15

7 group 1 (ACS patients without CP), group 2 (ACS patients with CP) and group 3 (CP only) formed the s

8 All the materials with rhBMP-2/ACS exhibited improvement on bone augmentation, mainly B

9 at received (n = 10) or not (n = 10) rhBMP-2/ACS in conjunction with one of the carriers: beta-trical

10 als exhibited a synergic effect with rhBMP-2/ACS, acting as suitable and viable carriers for vertical

11 emaining biomaterial was improved by rhBMP-2/ACS, mainly in BBM (P <0.01) and beta-TCP (P <0.01).

12 ished when the biomaterials received rhBMP-2/ACS.

13 pancreas operations abstracted in 2011-2017 ACS NSQIP Participant Use Data Files were included.

14 ent case-control studies with a total of 210 ACS patients and 210 controls.

15 Of 2921 ACS-NSQIP patients, 1562 (53%) underwent MIDP with 18% c

16 as analyzed in 1153 healthy controls and 699 ACS cases in Chinese Han population.

17 We studied 87 ACSs from 66 patients undergoing two-stage revision arth

18 d with improved outcomes consistently across ACS types compared with the no post-PCI infusion or hepa

19 Post-discharge bleeding after ACS is associated with a similar increase in subsequent

20 ation and revascularization management after ACS, compared to control group.

21 One to 12 months after ACS, 18,924 patients on high-intensity statin therapy we

22 o alirocumab or placebo 1 to 12 months after ACS.

23 arge bleeding and subsequent mortality after ACS according to index strategy (PCI or no PCI) and to c

24 independently associated with outcome after ACS and should be further investigated as a promising bi

25 tabilized (1 month post-randomization) after ACS.

26 uld be an independent treatment target after ACS.

27 All ACS NSQIP patients (17,228) undergoing surgery (2005 to

28 Adopting an ACS model of care increased adherence to practices for d

29 for performance improvement, and adopting an ACS model predicts better performance.

30 e and during a hospitalization for either an ACS (n = 10) or a VOC episode (n = 10).

31 mab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic l

32 luding a total of 270 patients presenting an ACS after a median time of 12 (interquartile range, 5-17

33 Patients with an ACS and histories of hypersensitivity reactions to ASA,

34 rnal validation in stable CAD (c = 0.65) and ACS (c = 0.68) demonstrated comparable performance.

35 Bundle adherence and ACS NSQIP outcomes were examined preimplementation versu

36 e is activated under hypoxic conditions, and ACS recovers carbon that would otherwise be lost from th

37 participants including healthy controls and ACS patients carried rs755622 GG (63.1% vs. 56.7%) and C

38 global dust storm, obtained by the NOMAD and ACS instruments onboard the ExoMars Trace Gas Orbiter.

39 and specificity of periprosthetic tissue and ACS sonication culture in detecting persistent infection

40 g patients with SCD hospitalized for VOC and ACS episodes to better understand ACS disease pathogenes

41 age, appearance or sex in the workplace and ACS (P <= 0.002).

42 report unfair treatment in the workplace and ACS due to race/ethnicity (P < 0.001).

43 ts, multiple heuristics that can approximate ACS(k) have been introduced.

44 a novel linear-time heuristic to approximate ACS(k), which is faster than computing the exact ACS(k)

45 multivariable analysis, revascularization at ACS time was associated with a reduction of the risk of

46 gene expression were identified during both ACS and VOC episodes.

47 cipients exhibited specific characteristics (ACS presentation, low use of invasive procedures, corona

48 Since computing ACS(k) takes O(n logkn) time and hence impractical for l

49 For this purpose 571 consecutive ACS patients receiving ticagrelor (n = 258, 45%) or pras

50 easure, ACS, and its k-mismatch counterpart, ACS(k), have been shown to produce results as effective

51 deline-adherent antibiotics had lower 30-day ACS-related (odds ratio [OR], 0.71; 95% CI, 0.50-1.00) a

52 diovascular risk for patients with different ACS phenotypes.Methods: Post hoc analysis of the ISAACC

53 t shifts to reduce pre-hospital delay during ACS events.

54 ts that were differentially expressed during ACS episodes, and 1802 transcripts during VOC episodes.

55 trated significantly altered pathways during ACS and VOC.

56 Top canonical pathways during ACS episodes were related to interferon signaling, neuro

57 icrobial function were down-regulated during ACS compared to VOC.

58 ted with higher severity of ACS, and earlier ACS onset time.

59 Early ACS diagnosis can reduce complications and risk of recur

60 (EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients

61 te coronary syndromes (NSTEACS) in the EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Patients

62 with a discharge diagnosis of SCD and either ACS or pneumonia.

63 tivariable regressions were used to evaluate ACS NSQIP predicted risk-adjusted effect of DCI on outco

64 exact ACS(k) while being closer to the exact ACS(k) values compared to previously published linear-ti

65 k), which is faster than computing the exact ACS(k) while being closer to the exact ACS(k) values com

66 ious heart disease and admission for a first ACS occurrence.

67 ith stenting of the culprit lesion following ACS.

68 tio 1.1, P = 0.01) even after accounting for ACS NSQIP predicted risk score.

69 adults with SCA and hospital admissions for ACS were identified through the discharge summaries, alo

70 study, including 1,701 patients admitted for ACS (NCT01335087).

71 r method produces a better approximation for ACS(k) and is applicable for the alignment-free comparis

72 resents a candidate prognostic biomarker for ACS in combination with a diagnosis of depressive disord

73 ed 15 differentially expressed cytokines for ACS.

74 ns: Analysis shows a treatment disparity for ACS for symptomatic HIV patients only as symptomatic HIV

75 e proportion of pre-hospital delays >2 h for ACS events, including asymptomatic MI, compared with sym

76 vided in 10654 of 14480 hospitalizations for ACS (73.6%).

77 rial involving 308 patients hospitalized for ACS with elevated LDL-C levels (>=1.8 mmol/l on high-int

78 In patients undergoing PCI for ACS, spontaneous events predominate after 30 days, with

79 I) or cardiovascular death following PCI for ACS.

80 interval [CI]: 46% to 63%) of ED visits for ACS events <2 h compared with 10% (95% CI: 2% to 27%) in

81 m senescent P3 cells or circulating MPs from ACS patients induced increased senescence-associated bet

82 Depletion of endothelial-derived MPs from ACS patients reduced the induction of senescence.

83 levels were analyzed in serum obtained from ACS patients (n = 1,146) on the first morning after hosp

84 ped using an orthogonal strategy on the full ACS subcohort.

85 Further, ACS and acute vasoccclusive pain crises (VOC) have overl

86 tion based on the concept of the generalized ACS approach.

87 Ensuring equity and inclusion may help ACS attract and retain the best and brightest without fe

88 tside hospital, emergency status, and higher ACS NSQIP predicted risk scores (all P < 0.05).

89 metric for socioeconomic distress, improves ACS NSQIP risk-adjustment to predict outcomes and hospit

90 In ACS patients with or without ST-segment elevation, the p

91 In ACS, FFR was performed in 1.4 lesions per patient, mostl

92 se clinical association of hyperglycaemia in ACS can be replicated in preclinical cellular models of

93 was to characterize equity and inclusion in ACS.

94 ic application of PKCalphabeta inhibition in ACS associated with hyperglycaemia.

95 The MIF level in ACS patients with CC genotype was significantly higher t

96 esentation, with a hazard ratio for MACCE in ACS patients of 0.67 (95% CI: 0.55 to 0.81) and the haza

97 workplace than at academic conferences or in ACS.

98 of hyperglycaemia with an adverse outcome in ACS.

99 methylation on long-term cardiac outcomes in ACS were found.

100 potential new avenue to improve outcomes in ACS.

101 full or low post-PCI bivalirudin regimen in ACS patients with or without ST-segment elevation.

102 l benefit of adding alirocumab to statins in ACS patients with prior CABG in a pre-specified analysis

103 steopontin might be a biomarker for incident ACS, using osteopontin adds moderately to traditional ca

104 rther examined their relations with incident ACS among 318 case-control pairs nested within the Dongf

105 concentrations were associated with incident ACS, and the multivariable-adjusted odds ratio (95% conf

106 Over a 5~12 year follow-up after the index ACS, time to major adverse cardiac event (MACE) was inve

107 treated with or without PCI for their index ACS (p for interaction = 0.240).

108 gical outcomes and should be integrated into ACS NSQIP risk models.

109 nment of quality improvement registries like ACS-NSQIP.

110 Plastid-localized ACS metabolizes cellular acetate and contributes to the

111 ently, the average common substring measure, ACS, and its k-mismatch counterpart, ACS(k), have been s

112 come was a composite of all-cause mortality, ACS, ischemia-driven (unplanned) urgent revascularizatio

113 between the model NiAz system and the native ACS enzyme, highlighting the potential for related react

114 in patients with ACS as in patients with non-ACS (major cardiovascular event, 8.0% versus 8.5%; P=0.8

115 administered in 1,068 (STEMI, n = 519; NSTE-ACS, n = 549) patients.

116 mary outcome did not differ in STEMI or NSTE-ACS patients who received or did not receive post-PCI bi

117 es were verified in an independent post NSTE-ACS cohort (N = 96).

118 ment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T.

119 n-ST elevation acute coronary syndrome (NSTE-ACS) event.

120 ent elevation acute coronary syndromes (NSTE-ACS) and planned invasive management.

121 ent elevation acute coronary syndromes [NSTE-ACS], n = 213), whereas the low-dose regimen was adminis

122 In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor

123 re identified and among them 2066 (0.40%) of ACS patients had diagnosis of HIV (asymptomatic and symp

124 Viruses were detected in 50% of ACS cases and 20% of VOC cases.

125 modestly improved the predictive ability of ACS beyond the Framingham risk scores.

126 rth quartile levels of CCL21 on admission of ACS had a significantly higher long-term (median 98 mont

127 Following analysis of ACS-NSQIP data, early removal demonstrated significantly

128 echanistic approach to the categorization of ACS to provide a framework for future tailoring, triage,

129 e discuss five non-atherosclerotic causes of ACS, including spontaneous coronary artery dissection, c

130 x of suspicion for other important causes of ACS.

131 In this retrospective cohort of ACS, BB improved in-hospital and 1-month mortality in pa

132 with a survey to examine the demographics of ACS surgeons, the exclusionary or biased behaviors they

133 important predictors for the development of ACS.

134 2016 to identify patients with diagnosis of ACS (ST-elevation and non ST-elevation myocardial infarc

135 , 515,016 patients with primary diagnosis of ACS where identified and among them 2066 (0.40%) of ACS

136 Cold stress promotes the expression of ACS and IDH which may increase the synthesis of citrate,

137 ctrum of clinical and laboratory features of ACS and to assess the predisposing factors and predictor

138 In patients without a history of ACS, chronic cocaine use was not associated with signifi

139 mprove both the prevention and management of ACS post-TAVR.

140 for these non-atherosclerotic mechanisms of ACS are reviewed.

141 replicated in preclinical cellular models of ACS and (ii) determine the importance of PKCalpha/beta a

142 tant contributors to a substantial number of ACS events and require different diagnostic and therapeu

143 lasma MIF level was also measured in part of ACS patients (139/19.9%) and healthy controls (129/11.2%

144 cardiovascular status at the early phase of ACS.

145 , has not been studied in the acute phase of ACS.

146 ab initiated during the in-hospital phase of ACS.

147 n of FFR into the decision-making process of ACS patients with obstructive coronary artery disease is

148 Since the prognosis of ACS is directly associated with timely initiation of rev

149 ation predicted worse long-term prognosis of ACS only in the presence of depressive disorder with sig

150 To decrease the risk of ACS and related CVDs and to reduce associated costs to h

151 with rs755622 C allele had a higher risk of ACS compared to other genotypes (AOR = 1.278, 95% CI: 1.

152 allele is associated with increased risk of ACS.

153 morphism may help for predicting the risk of ACS.

154 K9 antibody in the very high-risk setting of ACS, evolocumab added to high-intensity statin therapy w

155 were also correlated with higher severity of ACS, and earlier ACS onset time.

156 This is the first survey of ACS surgeons on equity and inclusion.

157 e discrepancy in the average age in years of ACS (70) and ASA (66) presidents compared to the AWS (51

158 ce was worse than at academic conferences or ACS.

159 ently adjudicated as true- or false-positive ACS events.

160 S2D) times were calculated for true-positive ACS ED visits triggered by 3 possible prompts: alarm onl

161 Post-ACS death, myocardial infarction, stroke, and overall ma

162 e-threatening bleeding (landmark 7 days post-ACS) and subsequent all-cause mortality was evaluated in

163 th ezetimibe added to statin therapy in post-ACS patients.

164 Patients (n = 18,924) 1 to 12 months post-ACS with elevated atherogenic lipoprotein levels despite

165 ifies a gradient of risk among patients post-ACS, offering the potential to identify higher-risk pati

166 e TRILOGY-ACS and independent Singapore post-ACS cohorts, suggesting the measurement of circulating m

167 nts with previous heart disease and previous ACS ("previous-CVD" phenotype; 19%).

168 previous heart disease and without previous ACS ("no-previous-CVD" phenotype; 81%) and patients with

169 ational Surgery Quality Improvement Program (ACS NSQIP) database does not account for these factors.

170 geons' National Quality Improvement Program (ACS-NSQIP) (88 centers; 2014-2016) to evaluate the assoc

171 tional Surgical Quality Improvement Program (ACS-NSQIP) 2014 Participant Use File was queried to iden

172 rgeons National Quality Improvement Program (ACS-NSQIP) database.

173 tional Surgical Quality Improvement Program (ACS-NSQIP) was queried for elective DPs from 2014 to 201

174 BG (n = 16,896); index CABG after qualifying ACS, but before randomization (n = 1,025); or CABG befor

175 n (n = 1,025); or CABG before the qualifying ACS (n = 1,003).

176 umab predicted the risk of MACE after recent ACS.

177 In patients with recent ACS and dyslipidemia despite intensive statin therapy, p

178 cation by alirocumab in patients with recent ACS and dyslipidemia despite intensive statin therapy.

179 Among patients with recent ACS and elevated atherogenic lipoproteins despite intens

180 A total of 969 patients with recent ACS were recruited at a tertiary university hospital in

181 We also now recognize ACS that occur without apparent epicardial coronary arte

182 l study, subjects at high risk for recurrent ACS events (n = 907) were randomized to control (Alarms

183 High-risk ACS subjects (N = 907) were randomized to a control (ala

184 53, known as the adenoma-carcinoma sequence (ACS).

185 function and to the American Cancer Society (ACS) cancer screening guidelines for average-risk popula

186 In 2016, the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable

187 timicrobial agent-containing cement spacers (ACSs) collected during second stages of staged revisions

188 riers to rhBMP-2/absorbable collagen sponge (ACS) in a vertical guided bone regeneration model.

189 participated in the Adolescent Cohort Study (ACS) between July 6, 2005 and April 23, 2007, through ei

190 leadership, the American College of Surgeon (ACS), American Surgical Association (ASA), Association o

191 international American College of Surgeons (ACS) Accredited Education Institutes (AEI).

192 The American College of Surgeons (ACS) has called for surgeons to alter opioid prescribing

193 created by the American College of Surgeons (ACS) to align trauma resource allocation with regional n

194 equity and inclusion in acute care surgery (ACS) with a survey to examine the demographics of ACS su

195 Acute care surgery (ACS), a specialty leveraging strengths of trauma systems

196 m (NVDRS) and the American Community Survey (ACS) to match individual and county-level risks.

197 ively used to guide treatment, 533 sustained ACS (excluding acute ST-segment-elevation myocardial inf

198 Acute chest syndrome (ACS) is a major complication of sickle cell anaemia (SCA

199 Acute chest syndrome (ACS) is a significant cause of morbidity and mortality i

200 ent disparities for Acute Coronary Syndrome (ACS) among HIV patients.

201 Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a

202 Patients with acute coronary syndrome (ACS) and history of coronary artery bypass grafting (CAB

203 isk and severity of acute coronary syndrome (ACS) are still limited.

204 presenting with an acute coronary syndrome (ACS) are unknown.

205 g-term prognosis of acute coronary syndrome (ACS) considering depression and cardiovascular status at

206 atients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in li

207 KI in patients with acute coronary syndrome (ACS) enrolled in the MATRIX-Access (Minimizing Adverse H

208 spital delay during acute coronary syndrome (ACS) events contributes to worse outcome.

209 ognostic factors of acute coronary syndrome (ACS) events following TAVR.

210 rt failure (HF) and acute coronary syndrome (ACS) including myocardial infarction (MI) are discussed.

211 ct in patients with acute coronary syndrome (ACS) is not well known.

212 tervention (PCI) in acute coronary syndrome (ACS) patients with or without ST-segment elevation remai

213 et lesion events in acute coronary syndrome (ACS) patients.

214 Among CVDs, the acute coronary syndrome (ACS) represents the most common cause of emergency hospi

215 roRNA, miR-146a, in acute coronary syndrome (ACS) subjects with and without chronic periodontitis (CP

216 on of patients with acute coronary syndrome (ACS) treated without percutaneous coronary intervention

217 on of patients with acute coronary syndrome (ACS) treated without revascularization remains unknown.

218 er of patients with acute coronary syndrome (ACS) using global assays and is a strong marker of futur

219 ubjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 17

220 who present with an acute coronary syndrome (ACS), but non-atherosclerotic processes are also importa

221 lticenter cohort of acute coronary syndrome (ACS), in relation to BB use: prior to admission, 24-hour

222 sms of MIF gene and acute coronary syndrome (ACS).

223 patients with prior acute coronary syndrome (ACS).

224 CCL19 and CCL21 in acute coronary syndrome (ACS).

225 ts in patients with acute coronary syndrome (ACS).

226 ecognized cause of acute coronary syndromes (ACS) afflicting predominantly younger to middle-aged wom

227 y in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target

228 d complications of acute coronary syndromes (ACS).

229 for patients with acute coronary syndromes (ACS).

230 a poor prompt for acute coronary syndromes (ACS).

231 The acetyl coenzyme A synthase (ACS) enzyme plays a central role in the metabolism of an

232 nogenic amino acid produced by ACC SYNTHASE (ACS).

233 with the expression of ATP-citrate synthase (ACS) and isocitrate dehydrogenase (IDH) genes in cold-tr

234 uster of wild-type (WT) Acetyl-CoA Synthase (ACS) and two variants, F229W and F229A.

235 lopropane-1-carboxylic acid (ACC) synthases (ACSs), the rate-limiting enzymes in ethylene biosynthesi

236 direct evidence that the acyl-CoA synthetase ACS-7, which was previously implicated in the attachment

237 e-activating enzymes, ACETYL-COA SYNTHETASE (ACS) in plastids and ACETATE NON-UTILIZING1 (ACN1) in pe

238 th CC genotype was significantly higher than ACS patients carrying GG genotype and healthy controls c

239 The ACS and ASA presidents' CVs displayed unsurpassed schola

240 The ACS clinical presentation consisted of non-ST-segment-el

241 In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable

242 ons of surgery, or surgery ongoing after the ACS announcement.

243 In conclusion, the ACS is characterized by a strongly altered global transl

244 ASCO endorsed the ACS HNC Survivorship Care Guideline, adding qualifying s

245 me significantly more negative following the ACS announcement (P = 0.037).

246 For the ACS and ASA cohort, 87% were male and 83% were White, co

247 llour and Roland Young were missing from the ACS and NOMAD Science Teams list, and minor changes have

248 w geriatric variables were imported from the ACS NSQIP geriatric pilot study.

249 CE-dechlorinating isolates obtained from the ACS pH 5.5 enrichment shared 98.6%, and 98.5% 16S rRNA g

250 llour and Roland Young were missing from the ACS Science Team list, and minor changes have been made

251 An alcove seen in the ACS crystal structure near the A-cluster, defined by hyd

252 of life data among 1261 participants in the ACS QUIK trial (Acute Coronary Syndrome Quality Improvem

253 set and verified by blind prediction in the ACS test set.

254 B Risk Model 5 (TRM5), was discovered in the ACS training set and verified by blind prediction in the

255 tic performance of the TRM5 signature in the ACS training set was excellent within 6 months of TB dia

256 patients >=65 years who underwent ES in the ACS-NSQIP 2017 database were included.

257 pato-pancreato-biliary (HPB) surgeons in the ACS-NSQIP HPB Collaborative conducted in 2017.

258 s Medical Institutions were entered into the ACS-NSQIP database.

259 implications for clinical management of the ACS for the future.

260 al pilot test), 2 parallel test forms of the ACS-ERRA were administered, each containing 40 cases, re

261 E and death in those with CABG preceding the ACS event.

262 ts The ASCO Expert Panel determined that the ACS HNC Survivorship Care Guideline, published in 2016,

263 holastic achievements were comparable to the ACS (and ASA) cohort in 9 and 12 of the 15 accessed metr

264 iffer between HCWs and non-HCWs prior to the ACS announcement (P = 0.98), but non-HCW sentiment becam

265 d hemoglobin SS participants compared to the ACS group.

266 an increasingly practical supplement to the ACS.

267 s in an attempt to detect methane, using the ACS and NOMAD instruments onboard the ESA-Roscosmos ExoM

268 Among average-risk survivors, adherence to ACS breast, cervical, and colorectal screening was 57.1%

269 nts After Acute Coronary Syndrome (TRANSLATE-ACS) study between April 1, 2010, and October 31, 2012.

270 TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal

271 ion in Acute Coronary Syndrome], and TRILOGY ACS [Platelet Inhibition to Clarify the Optimal Strategy

272 ent) risk scores were applied in the TRILOGY ACS population to evaluate their performance to predict

273 d by targeted rt-PCR in the complete TRILOGY-ACS cohort (N = 878) and compared with matched PR sample

274 ol (N = 76) cohort within the larger TRILOGY-ACS trial.

275 nsistently associated with PR in the TRILOGY-ACS and independent Singapore post-ACS cohorts, suggesti

276 or VOC and ACS episodes to better understand ACS disease pathogenesis.

277 outcomes and reduce cost barriers for wider ACS-NSQIP adoption.

278 were significantly higher in the cases with ACS than in the controls.

279 Hypothesis: HIV patient with ACS are as likely to receive cardiac revascularization r

280 value = 0.08).Conclusions: For patients with ACS and a specific phenotype, OSA is associated with an

281 g should be advocated in young patients with ACS and high LDL-C levels to allow prompt identification

282 Malnutrition is common among patients with ACS and is strongly associated with increased mortality

283 us Positive Airway Pressure in Patients with ACS and OSA) study, including 1,701 patients admitted fo

284 cular outcomes at 12 months in patients with ACS and was associated with a higher rate of mortality.

285 dical treatment was as safe in patients with ACS as in patients with non-ACS (major cardiovascular ev

286 asugrel or clopidogrel, 12,844 patients with ACS received at least 1 stent.

287 longitudinal bleeding risk in patients with ACS treated with DAPT without revascularization and help

288 Among medically managed patients with ACS treated with DAPT, the performances of the PRECISE-D

289 cores in the medically managed patients with ACS treated with DAPT.

290 ons and on clinical outcome of patients with ACS undergoing coronary angiography, as compared with pa

291 ysis could be used to identify patients with ACS who, despite antiplatelet therapy, remain at high ca

292 In elderly or low-weight patients with ACS, a reduced dose of prasugrel compared with the stand

293 Among the patients with ACS, fever (>38.5 degrees C), reduced oxygen saturation

294 l interventions on outcomes in patients with ACS.

295 onsequences of malnutrition in patients with ACS.

296 s applied to 5,062 consecutive patients with ACS.

297 ess of colchicine treatment in patients with ACS.

298 were adults (18-85 years) who presented with ACS and had evidence of coronary artery disease on coron

299 al patients presenting with VOC, but without ACS (controls).

300 Previously, we only knew WT ACS bound a single CO to form the A(red)-CO intermediate